The AASDHPPT Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted population of A-549 human lung adenocarcinoma cells, engineered to ablate the expression of the AASDHPPT gene. This polyclonal knockout cell model provides a heterogeneous loss-of-function tool for investigating the biological roles of 4′-phosphopantetheinyl transferase in lipid metabolism and cancer cell biology. The targeted disruption of AASDHPPT eliminates its catalytic activity, offering a robust system to study downstream effects on fatty acid synthase activation and de novo lipogenesis.
A-549 cells, originally derived from a 58-year-old male with lung adenocarcinoma, are widely employed as an alveolar epithelial model in cancer research, drug metabolism studies, and toxicology. Their epithelial phenotype and tumorigenic background make them particularly suitable for dissecting metabolic adaptations in non-small cell lung cancer. The A-549 cell line retains key signaling pathways relevant to lipid biosynthesis and proliferation, making it an appropriate host for interrogating the role of AASDHPPT in lipid-dependent cellular processes.
AASDHPPT encodes a 4′-phosphopantetheinyl transferase that catalyzes the transfer of the 4′-phosphopantetheine moiety from coenzyme A to a conserved serine residue on acyl carrier proteins (ACP) and peptidyl carrier proteins. This post-translational modification is essential for the activation of fatty acid synthase (FASN), a multi-enzyme complex central to de novo fatty acid biosynthesis. The AASDHPPT-FASN axis functions downstream of sterol regulatory element-binding protein 1 (SREBP1) and acetyl-CoA carboxylase, integrating nutritional and oncogenic signals to promote lipid synthesis. Disruption of AASDHPPT therefore uncouples the lipogenic machinery, impairing FASN maturation and subsequent lipid production.
In the context of A-549 adenocarcinoma cells, which exhibit heightened dependence on de novo lipogenesis for membrane biogenesis and energy production, ablation of AASDHPPT offers a valuable model for investigating metabolic vulnerabilities. The knockout population is expected to display reduced fatty acid synthesis, potentially affecting cell proliferation, survival, and sensitivity to metabolic stress. This model enables the dissection of how lung cancer cells rewire lipid metabolism and may reveal novel therapeutic targets within the fatty acid biosynthesis pathway.
Researchers can utilize these polyclonal knockout cells in a variety of functional assays, including Western blotting and RT-qPCR to confirm target disruption, C14-acetate incorporation assays to measure de novo fatty acid synthesis, and proliferation, apoptosis, or migration assays to assess phenotypic consequences. Additionally, these cells are suitable for drug sensitivity screens using FASN inhibitors or other metabolic interventions, aiding in the identification of synthetic lethal interactions. The AASDHPPT Knockout A-549 Polyclonal Cells provide a reliable platform for studying lipid metabolism in lung adenocarcinoma. For further technical details or assistance, please contact Ascent Research.
